Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
151.04
+2.75 (1.85%)
Aug 12, 2026, 10:19 AM EDT - Market open
Protagonist Therapeutics Revenue
Protagonist Therapeutics had revenue of $213.48M in the quarter ending June 30, 2026, with 3,749.17% growth. This brings the company's revenue in the last twelve months to $281.99M, up 34.81% year-over-year. In the year 2025, Protagonist Therapeutics had annual revenue of $46.02M, down -89.41%.
Revenue (ttm)
$281.99M
Revenue Growth
+34.81%
P/S Ratio
34.03
Revenue / Employee
$1,999,943
Employees
141
Market Cap
9.77B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 46.02M | -388.42M | -89.41% |
| Dec 31, 2024 | 434.43M | 374.43M | 624.06% |
| Dec 31, 2023 | 60.00M | 33.42M | 125.73% |
| Dec 31, 2022 | 26.58M | -776.00K | -2.84% |
| Dec 31, 2021 | 27.36M | -1.27M | -4.44% |
| Dec 31, 2020 | 28.63M | 28.40M | 12,293.07% |
| Dec 31, 2019 | 231.00K | -30.69M | -99.25% |
| Dec 31, 2018 | 30.93M | 10.86M | 54.14% |
| Dec 31, 2017 | 20.06M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bio-Techne | 1.21B |
| Ionis Pharmaceuticals | 874.09M |
| Krystal Biotech | 440.48M |
| Kymera Therapeutics | 105.00M |
| Cytokinetics | 67.67M |
| Crinetics Pharmaceuticals | 42.16M |
| Praxis Precision Medicines | 7.46M |
PTGX News
- 2 days ago - Protagonist Therapeutics price target raised to $170 from $145 at Truist - TheFly
- 2 days ago - Protagonist Therapeutics price target raised to $173 from $118 at Wedbush - TheFly
- 2 days ago - Protagonist Therapeutics upgraded to Buy from Neutral at Goldman Sachs - TheFly
- 6 days ago - Protagonist Therapeutics price target raised to $175 from $130 at Citi - TheFly
- 6 days ago - Protagonist Therapeutics price target raised to $173 from $116 at Clear Street - TheFly
- 6 days ago - Protagonist Therapeutics price target raised to $153 from $151 at Barclays - TheFly
- 6 days ago - Protagonist Therapeutics reports Q2 EPS $2.29, consensus $1.93 - TheFly
- 6 days ago - Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Accesswire